You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here Identifier : NCT01064856

Study of Adalimumab in Subjects With Peripheral Spondyloarthritis

    Status Completed
    Related Conditions
    Peripheral Spondyloarthritis

Enrollment Details

154 Worldwide Enrollment Goal


  • 1
  • 2
  • 3
  • 4
Study Type:  Interventional

This is a type III phase trial.

Brief summary


This study will study how well adalimumab works in the short and long term in subjects with peripheral spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.

Participant Attributes :
  • Male and Female
  • Ages 18 Years and older

Canada: 3

Montreal, QC
St. John's, NL
Would you like to know more about this trial?

Study Design

  • The method used to assign participants to an arm of a clinical trial, for example Randomized (assigned by chance) versus Non-randomized.



  • A target outcome that the study’s protocol aims to evaluate - things like: the occurrence of a disease, a symptom, sign, or lab abnormality, among others.

    Endpoint Classification

    Safety/Efficacy Study

  • The general design that shows how the medical interventions will be assigned to the participants, e.g., whether all patients will receive the same drug, or if different groups receive two or more different treatments in a particular order.

    Intervention Model

    Parallel Assignment

  • The general design that describes the strategy for identifying and following up with participants during observational studies.


    Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

  • This is the single main reason for carrying out the clinical trial. Reasons can include: treatment, prevention, diagnostic advances, supportive care, screening, or health services research, among others.



    • Adult subjects with inadequate response to >/= 2 non-steroidal anti-inflammatories (NSAIDs)
    • Subjects must have current arthritis or enthesitis dactylitis PLUS: meeting spondyloarthritis clinical criteria
    • Negative purified protein derivative (PPD) test and Chest X-Ray performed at Baseline Visit must be Negative
    • Ability to administer subcutaneous injections
    • General good health otherwise
    • Prior anti-tumor necrosis factor (TNF) therapy
    • Psoriasis or Psoriatic Arthritis
    • Fulfillment of modified New York criteria for Ankylosing Spondylitis
    • Recent infection requiring treatment
    • Significant medical events or conditions that may put patients at risk for participation
    • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
    • History of cancer, except successfully treated skin cancer
    • Recent history of drug or alcohol abuse

More on this trial